div class=ts-pagebuttonPage 1button div class=ts-image amp-img class=ts-thumb alt=Page 1: Currently the Food and Drug Administration FDA requires the demonstration of bioequivalence of generic drugs to innovator drugs in normal healthy subjects a criterion that may src=https:reader033vdocumentsusreader033viewer20220421165e93b2d1fe2026340c31a1d9html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 2button div class=ts-image amp-img class=ts-thumb alt=Page 2: Currently the Food and Drug Administration FDA requires the demonstration of bioequivalence of generic drugs to innovator drugs in normal healthy subjects a criterion that may src=https:reader033vdocumentsusreader033viewer20220421165e93b2d1fe2026340c31a1d9html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 3button div class=ts-image amp-img class=ts-thumb alt=Page 3: Currently the Food and Drug Administration FDA requires the demonstration of bioequivalence of generic drugs to innovator drugs in normal healthy subjects a criterion that may src=https:reader033vdocumentsusreader033viewer20220421165e93b2d1fe2026340c31a1d9html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 4button div class=ts-image amp-img class=ts-thumb alt=Page 4: Currently the Food and Drug Administration FDA requires the demonstration of bioequivalence of generic drugs to innovator drugs in normal healthy subjects a criterion that may src=https:reader033vdocumentsusreader033viewer20220421165e93b2d1fe2026340c31a1d9html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 5button div class=ts-image amp-img class=ts-thumb alt=Page 5: Currently the Food and Drug Administration FDA requires the demonstration of bioequivalence of generic drugs to innovator drugs in normal healthy subjects a criterion that may src=https:reader033vdocumentsusreader033viewer20220421165e93b2d1fe2026340c31a1d9html5thumbnails5jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 6button div class=ts-image amp-img class=ts-thumb alt=Page 6: Currently the Food and Drug Administration FDA requires the demonstration of bioequivalence of generic drugs to innovator drugs in normal healthy subjects a criterion that may src=https:reader033vdocumentsusreader033viewer20220421165e93b2d1fe2026340c31a1d9html5thumbnails6jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 7button div class=ts-image amp-img class=ts-thumb alt=Page 7: Currently the Food and Drug Administration FDA requires the demonstration of bioequivalence of generic drugs to innovator drugs in normal healthy subjects a criterion that may src=https:reader033vdocumentsusreader033viewer20220421165e93b2d1fe2026340c31a1d9html5thumbnails7jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 8button div class=ts-image amp-img class=ts-thumb alt=Page 8: Currently the Food and Drug Administration FDA requires the demonstration of bioequivalence of generic drugs to innovator drugs in normal healthy subjects a criterion that may src=https:reader033vdocumentsusreader033viewer20220421165e93b2d1fe2026340c31a1d9html5thumbnails8jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 9button div class=ts-image amp-img class=ts-thumb alt=Page 9: Currently the Food and Drug Administration FDA requires the demonstration of bioequivalence of generic drugs to innovator drugs in normal healthy subjects a criterion that may src=https:reader033vdocumentsusreader033viewer20220421165e93b2d1fe2026340c31a1d9html5thumbnails9jpg width=142 height=106 layout=responsive amp-img divdiv